Development of a multivariable improvement measure for gout
| Autor: | N. Lawrence Edwards, Naomi Schlesinger, Peter E. Lipsky, Anthony E. Yeo |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
lcsh:Diseases of the musculoskeletal system Gout Urate Oxidase Placebo law.invention Gout Suppressants Polyethylene Glycols Disease activity 03 medical and health sciences 0302 clinical medicine Randomized controlled trial law Internal medicine medicine Humans 030212 general & internal medicine Pegloticase 030203 arthritis & rheumatology business.industry Arthritis Gouty Tophus medicine.disease Rheumatology Uric Acid Treatment Outcome Orthopedic surgery Chronic Disease lcsh:RC925-935 business medicine.drug Research Article |
| Zdroj: | Arthritis Research & Therapy Arthritis Research & Therapy, Vol 22, Iss 1, Pp 1-10 (2020) |
| ISSN: | 1478-6362 1478-6354 |
| Popis: | Background Gout is a heterogeneous inflammatory disease with numerous clinical manifestations. A composite means to assess the impact of therapy on numerous aspects of gout could be useful. Methods Results from patients treated with pegloticase or placebo in two randomized clinical trials and their open-label extension were assessed using a novel evidence-based Gout Multivariable Improvement Measure (GMIM) derived from previously reported criteria for remission and complete response. Improvement was defined as serum urate (sU) Results Patients treated with pegloticase manifested a significantly greater GMIM20, 50, and 70 response vs those treated with placebo (GMIM20 at 6 months 37.1% vs 0%, respectively). Higher response rates were significantly more frequent in subjects with persistent urate lowering (GMIM 58.1% at 6 months) in response to pegloticase versus those with only transient urate lowering (GMIM 7.1% at 6 months). However, when the requirement for a decrease in sU to Conclusions GMIM captures changes in disease activity in response to treatment with pegloticase and may serve as an evidence-based tool for assessment of responses to other urate-lowering therapies in gout patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink